Annuncio • May 02
Vytrus Biotech, S.A., Annual General Meeting, Jun 02, 2026 Vytrus Biotech, S.A., Annual General Meeting, Jun 02, 2026. Location: calle blasco de garay 29-49, edifici cambra de comerc, terrassa., Spain Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €19.75, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 17x in the Personal Products industry in Europe. Total returns to shareholders of 506% over the past three years. New Risk • Apr 09
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (23% accrual ratio). Valuation Update With 7 Day Price Move • Mar 26
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €15.20, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 16x in the Personal Products industry in Europe. Total returns to shareholders of 375% over the past three years. Valuation Update With 7 Day Price Move • Mar 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €12.80, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 16x in the Personal Products industry in Europe. Total returns to shareholders of 277% over the past three years. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to €12.90, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 17x in the Personal Products industry in Europe. Total returns to shareholders of 286% over the past three years. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to €11.00, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 17x in the Personal Products industry in Europe. Total returns to shareholders of 228% over the past three years. Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €9.40, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 16x in the Personal Products industry in Europe. Total returns to shareholders of 185% over the past three years. Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €7.30, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 18x in the Personal Products industry in Europe. Total returns to shareholders of 124% over the past three years. New Risk • Sep 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 5.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (5.9% average weekly change). Minor Risk Market cap is less than US$100m (€45.1m market cap, or US$52.8m). Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €5.70, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Personal Products industry in Europe. Total returns to shareholders of 90% over the past three years. Buy Or Sell Opportunity • Jul 21
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 75% to €5.10. The fair value is estimated to be €4.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 17%. New Risk • Jul 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 5.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (5.1% average weekly change). Market cap is less than US$100m (€34.1m market cap, or US$40.1m). Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to €4.08, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Personal Products industry in Europe. Total returns to shareholders of 17% over the past three years. Annuncio • May 29
Vytrus Biotech, S.A. announced that it has received €1.2 million in funding from Boyser S.R.L and other investors Vytrus Biotech, S.A. announced a private placement of 506,329 common shares at a price of €2.37 per share for the gross proceeds of €1,200,000 on May 29, 2025. The transaction included participation from Boyser S.R.L and other investors. Annuncio • May 19
Vytrus Biotech, S.A., Annual General Meeting, Jun 17, 2025 Vytrus Biotech, S.A., Annual General Meeting, Jun 17, 2025. Location: calle blasco de garay 29-49, edifici cambra de comerc, terrassa., Spain Buy Or Sell Opportunity • May 15
Now 21% undervalued Over the last 90 days, the stock has risen 29% to €3.26. The fair value is estimated to be €4.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last year, while earnings per share has been flat. New Risk • Apr 28
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€24.1m market cap, or US$27.4m). Reported Earnings • Oct 15
First half 2024 earnings released: EPS: €0.068 (vs €0.053 in 1H 2023) First half 2024 results: EPS: €0.068 (up from €0.053 in 1H 2023). Revenue: €3.03m (up 21% from 1H 2023). Net income: €510.7k (up 42% from 1H 2023). Profit margin: 17% (up from 14% in 1H 2023). The increase in margin was driven by higher revenue. New Risk • Jul 17
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (5.0% increase in shares outstanding). Market cap is less than US$100m (€18.6m market cap, or US$20.2m). Annuncio • May 14
Vytrus Biotech, S.A., Annual General Meeting, Jun 12, 2024 Vytrus Biotech, S.A., Annual General Meeting, Jun 12, 2024. Location: cl blasco de garay 29-49, edifici cambra de comerc., terrassa Spain New Risk • Mar 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (4.4% average weekly change). Market cap is less than US$100m (€13.6m market cap, or US$14.9m). Reported Earnings • Oct 26
First half 2023 earnings released: EPS: €0.053 (vs €0.049 in 1H 2022) First half 2023 results: EPS: €0.053 (up from €0.049 in 1H 2022). Revenue: €2.50m (up 4.2% from 1H 2022). Net income: €358.9k (up 7.0% from 1H 2022). Profit margin: 14% (in line with 1H 2022). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. New Risk • Oct 21
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (€4.6m revenue, or US$4.9m). Market cap is less than US$100m (€17.1m market cap, or US$18.1m). New Risk • Oct 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (€4.5m revenue, or US$4.7m). Market cap is less than US$100m (€17.4m market cap, or US$18.3m). Valuation Update With 7 Day Price Move • Sep 18
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €2.10, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Personal Products industry in Europe. Total loss to shareholders of 35% over the past year. Reported Earnings • Mar 30
Full year 2022 earnings released Full year 2022 results: Revenue: €4.48m (up 28% from FY 2021). Net income: €605.3k (up 35% from FY 2021). Profit margin: 14% (in line with FY 2021). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Personal Products industry in Europe. Buying Opportunity • Mar 28
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 5.9%. The fair value is estimated to be €4.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 48% over the last year. Meanwhile, the company has become profitable. Buying Opportunity • Feb 27
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 4.1%. The fair value is estimated to be €4.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 48% over the last year. Meanwhile, the company has become profitable. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Oct 25
First half 2022 earnings released First half 2022 results: Net income: €335.3k (up €335.3k from 1H 2021). Revenue is forecast to grow 5.9% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Personal Products industry in Europe.